Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Early Phase 1
2(66.7%)
Phase 1
1(33.3%)
3Total
Early Phase 1(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07306156Phase 1Recruiting

GP350 CAR-T for Relapse/Refractory and Epstein-Barr Virus Infection Associated Lymphoid Neoplasms

Role: collaborator

NCT06642025Early Phase 1Recruiting

EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia

Role: collaborator

NCT06196658Early Phase 1Not Yet Recruiting

Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer

Role: collaborator

All 3 trials loaded